International journal of dermatology · 1993
Effect of topical paromomycin on cell-mediated immunity during cutaneous leishmaniasis.
Клиническое исследованиеКонтролируемое клиническое исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПоддержка службы здравоохранения СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Frankenburg S, Gross A, Jonas F, Klaus S
Аннотация
BACKGROUND: The aim of this study was to evaluate the effect of topical paromomycin treatment on the development of immunity during cutaneous leishmaniasis.
METHODS: Three parameters of immunity were measured in the course of the disease: leishmanicidal effector activity, lymphocyte proliferation (cell-mediated immunity), and antibody levels (humoral immunity). Peripheral blood specimens of 55 treated and 36 untreated patients were tested.
RESULTS: The main results of this study showed that there was a significant delay in the development of leishmanicidal effector activity and to a lesser extent also a delay in the development of antigen-specific proliferative response in the treated compared with the untreated group. No difference was observed between the groups regarding the values achieved in the various tests.
CONCLUSIONS: These results suggest that topical paromomycin treatment delays the development of cell-mediated immunity but does not affect the levels of immunity that are eventually achieved.
METHODS: Three parameters of immunity were measured in the course of the disease: leishmanicidal effector activity, lymphocyte proliferation (cell-mediated immunity), and antibody levels (humoral immunity). Peripheral blood specimens of 55 treated and 36 untreated patients were tested.
RESULTS: The main results of this study showed that there was a significant delay in the development of leishmanicidal effector activity and to a lesser extent also a delay in the development of antigen-specific proliferative response in the treated compared with the untreated group. No difference was observed between the groups regarding the values achieved in the various tests.
CONCLUSIONS: These results suggest that topical paromomycin treatment delays the development of cell-mediated immunity but does not affect the levels of immunity that are eventually achieved.